Q2 FY26 quarterly results (July-September 2025)

5,073 companies have declared Q2 FY26 results so far, the latest on 14 Sep 2026.

Across the 4,407 non-financial companies with a year-ago quarter to compare, sales grew +12.8% and net profit +57.5% year on year, and the combined operating margin widened 96 bps to 14.3%.

For the 146 banks and lenders, net interest income grew +6.3% and net profit +7.3%.

54% of companies grew net profit; 337 turned a loss into a profit; 34% beat their own profit trend and 50% fell short of it.

Updated 19 Oct 2026, 11:18 IST 5073 declared
The next results season has started: 164 companies have filed results for the quarter ended 30 Sep 2026. See them →

Q2 FY26 scoreboard

Sales growth
+12.8%
YoY, 4407 companies combined; median +8.4%
Net profit growth
+57.5%
YoY combined; median +9.4%
Operating margin
14.3%
+96 bps YoY
Grew profit
54%
337 turnarounds, 405 into loss
Vs own profit trend
34% / 50%
above / below, 16% in line
Banks: NII growth
+6.3%
146 lenders; profit +7.3%
Price since results
-10.0%
median; 0% of 1 stocks up
Other-income heavy
1339
25%+ of pre-tax profit from other income & one-offs

Latest Q2 FY26 results 5073

Page 116 of 170

Indo Euro Indchem Ltd

524458 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +350% above its own trend
  • Operating margin expanded 1687 bps YoY
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +208.8%+82.5% 2.81.50.9
Operating profit loss narrowedto loss -0.00.1-0.2
OPM % +1687 bps-785 bps -0.7%7.1%-17.6%
Other income -25.0%+0.0% 0.10.10.2
Net profit +800.0%-40.0% 0.10.10.0
PAT margin % +210 bps-654 bps 3.2%9.7%1.1%
EPS (₹) +900.0%-41.2% 0.100.170.01

Quality of profit

Pre-tax profit ₹0.1 Cr: core business −₹0.0 Cr, other income ₹0.1 Cr.

Core profit YoY: loss narrowed · reported profit +800.0%

Cash & debt

FY25 cash from operations ₹0.4 Cr: 106% of FY25 net profit of ₹0.4 Cr.

Borrowings nil at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹0.7₹2.8 +324.8% above
Net profit₹0.0₹0.1 +350.0% above

Riddhi Siddhi Gluco Biols Ltd

524480 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit +115% above its own trend
  • Operating margin contracted 599 bps YoY
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales -34.7%-79.4% 32.015549.0
Operating profit -66.7%— 2.00.06.0
OPM % -599 bps+625 bps 6.2%0.0%12.2%
Other income +10.5%+5.0% 21.020.019.0
Net profit? +7.7%+75.0% 14.08.013.0
PAT margin % +1722 bps+3859 bps 43.8%5.2%26.5%
EPS (₹) +0.3%+63.6% 18.9911.6118.93

Quality of profit

Pre-tax profit ₹15.0 Cr: core business −₹5.0 Cr, other income ₹21.0 Cr, exceptional & other items −₹1.0 Cr.

Core profit YoY: to loss · reported profit +7.7%

Cash & debt

FY25 cash from operations −₹28.0 Cr.

Borrowings ₹101 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹80.1₹32.0 -60.1% below
Net profit₹6.5₹14.0 +115.4% above

SVC INDUSTRIES Ltd

524488 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin expanded 705 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +140.5%-23.8% 2.02.60.8
Operating profit loss narrowedloss narrowed -0.1-0.2-0.1
OPM % +705 bps+356 bps -2.5%-6.0%-9.5%
Other income —-100.0% 0.00.00.0
Net profit loss narrowedloss narrowed -0.5-0.7-0.6
PAT margin % +3993 bps-32 bps -26.7%-26.4%-66.7%
EPS (₹) —loss narrowed -0.03-0.04-0.03

Quality of profit

Pre-tax profit −₹0.5 Cr: core business −₹0.5 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹1.5 Cr.

Borrowings ₹175 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹1.7₹2.0 +20.2% above

Raaj Medisafe India Ltd

524502 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +37% above its own trend
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +68.7%+16.2% 18.415.810.9
Operating profit +59.0%+5.0% 2.82.61.7
OPM % -91 bps-161 bps 14.9%16.6%15.9%
Other income —— 0.20.00.0
Net profit +78.4%+18.5% 1.71.51.0
PAT margin % +51 bps+18 bps 9.4%9.2%8.9%
EPS (₹) +80.8%+18.9% 1.321.110.73

Quality of profit

Core 87%Other income & one-offs 13%

Pre-tax profit ₹1.7 Cr: core business ₹1.5 Cr, other income ₹0.2 Cr.

Core profit YoY: +31.6% · reported profit +78.4%

Cash & debt

FY25 cash from operations −₹0.1 Cr: -1% of FY25 net profit of ₹6.5 Cr.

Borrowings ₹34.6 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹15.7₹18.4 +16.9% above
Net profit₹1.3₹1.7 +37.1% above

Coral Laboratories Ltd

524506 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +18% above its own trend
  • Operating margin expanded 576 bps YoY
  • 41% of pre-tax profit came from other income and one-off items
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales -41.0%+1.1% 19.018.832.2
Operating profit -24.1%+126.6% 4.92.26.5
OPM % +576 bps+1438 bps 26.0%11.6%20.2%
Other income +19.3%+47.8% 3.02.02.5
Net profit -8.8%+127.3% 5.82.66.4
PAT margin % +1079 bps+1698 bps 30.6%13.6%19.8%
EPS (₹) -8.8%+127.2% 16.297.1717.86

Quality of profit

Core 59%Other income & one-offs 41%

Pre-tax profit ₹7.4 Cr: core business ₹4.4 Cr, other income ₹3.0 Cr.

Core profit YoY: -26.7% · reported profit -8.8%

Cash & debt

FY25 cash from operations −₹1.0 Cr: -4% of FY25 net profit of ₹24.1 Cr.

Borrowings ₹4.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹36.2₹19.0 -47.4% below
Net profit₹5.0₹5.8 +17.5% above

Tulasee Bio Ethanol Ltd

524514 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss widenedloss narrowed -0.0-0.1-0.0
Other income —— 0.00.00.0
Net profit loss widenedloss narrowed -0.0-0.1-0.0
EPS (₹) loss widenedloss narrowed -0.05-0.12-0.03

Quality of profit

Pre-tax profit −₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations ₹0.0 Cr.

Borrowings ₹7.4 Cr at Mar 2025.

Bacil Pharma Ltd

524516 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss narrowed -0.0-0.1-0.1
Other income -91.1%-95.0% 0.11.00.6
Net profit -97.9%-98.5% 0.00.70.5
EPS (₹) -98.8%-97.9% 0.010.470.81

Quality of profit

Pre-tax profit ₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.1 Cr.

Core profit YoY: loss narrowed · reported profit -97.9%

Cash & debt

FY25 cash from operations ₹0.4 Cr: 98% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹0.2 Cr at Mar 2025.

KMC Speciality Hospitals (India) Ltd

524520 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +243% above its own trend
  • Operating margin expanded 479 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +33.9%+11.9% 75.067.056.0
Operating profit +61.5%+31.2% 21.016.013.0
OPM % +479 bps+412 bps 28.0%23.9%23.2%
Other income —+0.0% 1.01.00.0
Net profit +175.0%+37.5% 11.08.04.0
PAT margin % +752 bps+273 bps 14.7%11.9%7.1%
EPS (₹) +175.0%+43.5% 0.660.460.24

Quality of profit

Core 93%Other income & one-offs 7%

Pre-tax profit ₹15.0 Cr: core business ₹14.0 Cr, other income ₹1.0 Cr.

Core profit YoY: +180.0% · reported profit +175.0%

Cash & debt

FY25 cash from operations ₹58.0 Cr: 252% of FY25 net profit of ₹23.0 Cr.

Borrowings ₹89.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹72.7₹75.0 +3.1% in line
Net profit₹3.2₹11.0 +243.1% above

Laffans Petrochemicals Ltd

524522 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Into loss: a profit a year ago
  • Profit -417% below its own trend
  • Operating margin contracted 1584 bps YoY
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales -61.1%+474.2% 1.80.34.6
Operating profit loss narrowedloss widened -0.6-0.5-0.9
OPM % -1584 bps— -34.8%—-19.0%
Other income to lossto loss -3.87.42.6
Net profit to lossto loss -4.36.41.1
EPS (₹) to lossto loss -5.398.021.40

Quality of profit

Pre-tax profit −₹4.6 Cr: core business −₹0.8 Cr, other income −₹3.8 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹6.5 Cr: -325% of FY25 net profit of ₹2.0 Cr.

Borrowings ₹0.4 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹2.3₹1.8 -23.2% below
Net profit₹1.4−₹4.3 -416.9% below

Bhaskar Agrochemicals Ltd

524534 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin contracted 349 bps YoY
  • FY25 operating cash flow was only 26% of profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +25.5%+74.4% 40.523.232.2
Operating profit -0.9%+626.0% 5.30.75.3
OPM % -349 bps+996 bps 13.1%3.1%16.6%
Other income —— 0.00.00.0
Net profit +3.5%from loss 3.3-0.23.2
PAT margin % -172 bps+901 bps 8.1%-0.9%9.8%
EPS (₹) +3.6%from loss 6.30-0.406.08

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹4.4 Cr: core business ₹4.4 Cr, other income ₹0.0 Cr.

Core profit YoY: -2.9% · reported profit +3.5%

Cash & debt

FY25 cash from operations ₹1.0 Cr: 26% of FY25 net profit of ₹3.9 Cr.

Borrowings ₹20.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹51.4₹40.5 -21.3% below
Net profit₹3.5₹3.3 -5.5% in line

Sharma East India Hospitals & Medical Research Ltd

524548 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -26% below its own trend
  • Operating margin contracted 228 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +4.0%-1.0% 9.49.59.0
Operating profit -15.3%+2.2% 0.90.91.1
OPM % -228 bps+31 bps 10.0%9.7%12.3%
Other income +25.0%+25.0% 0.10.00.0
Net profit -5.9%+0.0% 0.30.30.3
PAT margin % -36 bps+3 bps 3.4%3.4%3.8%

Quality of profit

Core 89%Other income & one-offs 11%

Pre-tax profit ₹0.5 Cr: core business ₹0.4 Cr, other income ₹0.1 Cr.

Core profit YoY: -2.4% · reported profit -5.9%

Cash & debt

FY25 cash from operations ₹6.7 Cr: 535% of FY25 net profit of ₹1.2 Cr.

Borrowings ₹2.3 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹13.9₹9.4 -32.7% below
Net profit₹0.4₹0.3 -25.9% below

Gayatri BioOrganics Ltd

524564 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss widenedloss narrowed -0.1-0.2-0.1
Other income —— 0.00.00.0
Net profit loss widenedloss narrowed -0.2-0.3-0.2
EPS (₹) loss widened— -0.03-0.03-0.02

Quality of profit

Pre-tax profit −₹0.2 Cr: core business −₹0.2 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations −₹0.6 Cr.

Borrowings ₹36.9 Cr at Mar 2025.

Pharmaids Pharmaceuticals Ltd

524572 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Operating margin contracted 1580 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +64.3%+29.3% 8.66.75.2
Operating profit loss widenedloss narrowed -5.3-5.4-2.4
OPM % -1580 bps+1884 bps -61.8%-80.6%-46.0%
Other income —— 3.00.00.1
Net profit? loss widenedloss narrowed -2.6-5.3-2.3
PAT margin % +1347 bps+4928 bps -29.8%-79.1%-43.3%
EPS (₹) loss widenedloss narrowed -0.71-1.39-0.55

Quality of profit

Pre-tax profit −₹3.7 Cr: core business −₹6.7 Cr, other income ₹3.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations −₹14.0 Cr.

Borrowings ₹39.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹7.4₹8.6 +16.7% above

Vivid Global Industries Ltd

524576 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -17% below its own trend
  • Operating margin expanded 126 bps YoY
  • 65% of pre-tax profit came from other income and one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +97.7%+32.2% 13.910.57.0
Operating profit +181.0%+168.2% 0.60.20.2
OPM % +126 bps+215 bps 4.2%2.1%3.0%
Other income -11.8%+0.0% 0.10.10.2
Net profit +41.7%+54.5% 0.20.10.1
PAT margin % -48 bps+18 bps 1.2%1.0%1.7%
EPS (₹) +46.2%+58.3% 0.190.120.13

Quality of profit

Core 35%Other income & one-offs 65%

Pre-tax profit ₹0.2 Cr: core business ₹0.1 Cr, other income ₹0.1 Cr.

Core profit YoY: from loss · reported profit +41.7%

Cash & debt

FY25 cash from operations ₹2.2 Cr: 574% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹2.5 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹6.9₹13.9 +103.0% above
Net profit₹0.2₹0.2 -16.7% below

Priya Ltd

524580 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss narrowed— -0.0-0.0-0.1
Other income -100.0%— 0.00.00.0
Net profit loss narrowedloss widened -0.9-0.9-1.0
EPS (₹) loss narrowedloss widened -3.16-3.13-3.33

Quality of profit

Pre-tax profit −₹0.9 Cr: core business −₹0.9 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.2 Cr.

Borrowings ₹26.1 Cr at Mar 2025.

Tirupati Starch & Chemicals Ltd

524582 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit -99% below its own trend
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales -13.6%-3.3% 89.292.2103
Operating profit -15.5%-37.3% 4.26.85.0
OPM % -11 bps-258 bps 4.8%7.3%4.9%
Other income +184.6%+184.6% 0.40.10.1
Net profit? -98.5%-99.4% 0.01.60.7
PAT margin % -63 bps-175 bps 0.0%1.8%0.6%
EPS (₹) -98.6%-99.4% 0.011.690.69

Quality of profit

Pre-tax profit ₹0.1 Cr: core business −₹0.3 Cr, other income ₹0.4 Cr.

Core profit YoY: to loss · reported profit -98.5%

Cash & debt

FY25 cash from operations ₹49.0 Cr: 651% of FY25 net profit of ₹7.5 Cr.

Borrowings ₹136 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹120₹89.2 -25.7% below
Net profit₹1.3₹0.0 -99.2% below

Hemo Organic Ltd

524590 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss narrowed -0.0-0.1-0.1
Other income —— 0.00.00.0
Net profit loss narrowedloss narrowed -0.0-0.1-0.1
EPS (₹) loss narrowedloss narrowed -0.09-0.26-0.23

Quality of profit

Pre-tax profit −₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.4 Cr: -171% of FY25 net profit of ₹0.2 Cr.

Borrowings ₹1.5 Cr at Mar 2025.

Jaysynth Orgochem Ltd

524592 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit +31% above its own trend
  • Operating margin contracted 132 bps YoY
  • FY25 operating cash flow was only 45% of profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +14.5%+11.5% 65.859.057.5
Operating profit +0.8%+72.0% 6.43.76.3
OPM % -132 bps+341 bps 9.7%6.3%11.0%
Other income +185.5%from loss 1.6-0.10.6
Net profit? +16.7%+187.8% 5.01.74.2
PAT margin % +14 bps+461 bps 7.5%2.9%7.4%
EPS (₹) +19.4%+184.6% 0.370.130.31

Quality of profit

Core 77%Other income & one-offs 23%

Pre-tax profit ₹6.8 Cr: core business ₹5.2 Cr, other income ₹1.6 Cr.

Core profit YoY: +0.6% · reported profit +16.7%

Cash & debt

FY25 cash from operations ₹7.0 Cr: 45% of FY25 net profit of ₹15.6 Cr.

Borrowings ₹46.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹64.5₹65.8 +2.1% in line
Net profit₹3.8₹5.0 +30.6% above

Aeonx Digital Technology Ltd

524594 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit -67% below its own trend
  • Operating margin contracted 921 bps YoY
  • All of pre-tax profit came from other income or one-off items
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +3.7%-34.6% 10.616.310.3
Operating profit to lossloss widened -0.1-0.10.8
OPM % -921 bps-70 bps -1.3%-0.6%7.9%
Other income -0.8%+11.3% 1.21.11.2
Net profit? -72.7%-28.6% 0.30.51.3
PAT margin % -919 bps+28 bps 3.3%3.0%12.5%
EPS (₹) -72.7%-29.0% 0.761.072.78

Quality of profit

Pre-tax profit ₹0.6 Cr: core business −₹0.6 Cr, other income ₹1.2 Cr.

Core profit YoY: to loss · reported profit -72.7%

Cash & debt

FY25 cash from operations −₹4.6 Cr: -114% of FY25 net profit of ₹4.0 Cr.

Borrowings ₹0.9 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹11.9₹10.6 -10.8% below
Net profit₹1.0₹0.3 -66.5% below

Bandaram Pharma Packtech Ltd

524602 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit -89% below its own trend
  • Operating margin contracted 1205 bps YoY
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +93.0%+69.4% 13.78.17.1
Operating profit -58.7%-28.6% 0.50.61.1
OPM % -1205 bps-450 bps 3.3%7.8%15.3%
Other income —— 0.00.00.0
Net profit? -91.0%+200.0% 0.10.00.7
PAT margin % -899 bps+19 bps 0.4%0.2%9.4%
EPS (₹) -96.4%+0.0% 0.020.020.56

Quality of profit

Core 86%Other income & one-offs 14%

Pre-tax profit ₹0.1 Cr: core business ₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: -91.2% · reported profit -91.0%

Cash & debt

FY25 cash from operations −₹4.9 Cr: -503% of FY25 net profit of ₹1.0 Cr.

Borrowings ₹17.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹6.0₹13.7 +129.9% above
Net profit₹0.5₹0.1 -88.7% below

Adline Chem Lab Ltd

524604 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss narrowedloss widened -0.1-0.0-0.1
Other income —— 0.00.00.0
Net profit loss narrowedloss widened -0.1-0.1-0.1
EPS (₹) loss narrowedloss widened -0.12-0.09-0.15

Quality of profit

Pre-tax profit −₹0.1 Cr: core business −₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: loss narrowed

Cash & debt

FY25 cash from operations −₹0.2 Cr.

Borrowings ₹1.5 Cr at Mar 2025.

Beryl Drugs Ltd

524606 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +100% above its own trend
  • Operating margin expanded 422 bps YoY
  • Core business grew faster than reported profit (core profit +136%)
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales -8.5%+6.8% 5.24.85.6
Operating profit +30.4%+32.7% 0.70.60.6
OPM % +422 bps+276 bps 14.1%11.4%9.9%
Other income —— 0.00.00.0
Net profit +0.0%-50.0% 0.00.00.0
PAT margin % +2 bps-22 bps 0.2%0.4%0.2%
EPS (₹) +0.0%-50.0% 0.020.040.02

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹0.3 Cr: core business ₹0.3 Cr, other income ₹0.0 Cr.

Core profit YoY: +136.4% · reported profit +0.0%

Cash & debt

FY25 cash from operations ₹2.6 Cr: 455% of FY25 net profit of ₹0.6 Cr.

Borrowings ₹4.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹4.2₹5.2 +24.2% above
Net profit₹0.0₹0.0 +100.0% above

IEL Ltd

524614 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Into loss: a profit a year ago
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —— 0.00.00.0
Operating profit loss widenedloss narrowed -0.1-0.8-0.1
Other income -100.0%-100.0% 0.00.10.2
Net profit to lossloss narrowed -0.1-0.70.1
EPS (₹) to lossloss narrowed -0.01-0.060.01

Quality of profit

Pre-tax profit −₹0.1 Cr: core business −₹0.1 Cr, other income ₹0.0 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations ₹2.1 Cr: 491% of FY25 net profit of ₹0.4 Cr.

Borrowings ₹0.9 Cr at Mar 2025.

iStreet Network Ltd

524622 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Turnaround: profit against a loss a year ago
  • Operating cash flow was negative in FY25 despite a profit
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales —+41.0% 18.613.20.0
Operating profit from loss+34.3% 0.90.7-0.0
OPM % —-24 bps 4.8%5.1%—
Other income —-100.0% 0.01.80.0
Net profit from loss-63.6% 0.92.5-0.0
PAT margin % —-1384 bps 4.8%18.7%—
EPS (₹) from loss-63.8% 0.421.16-0.02

Quality of profit

Core 100%Other income & one-offs 0%

Pre-tax profit ₹0.9 Cr: core business ₹0.9 Cr, other income ₹0.0 Cr.

Core profit YoY: from loss

Cash & debt

FY25 cash from operations −₹0.0 Cr: -8% of FY25 net profit of ₹0.2 Cr.

Borrowings ₹1.8 Cr at Mar 2025.

Gagan Gases Ltd

524624 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Into loss: a profit a year ago
  • Profit -106% below its own trend
  • Operating margin contracted 639 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +15.4%+91.9% 1.60.91.4
Operating profit -90.0%from loss 0.0-0.10.1
OPM % -639 bps+642 bps 0.6%-5.8%7.0%
Other income —— 0.00.00.0
Net profit to lossloss narrowed -0.0-0.10.1
PAT margin % -620 bps+753 bps -0.6%-8.1%5.6%
EPS (₹) to lossloss narrowed -0.02-0.150.18

Quality of profit

Pre-tax profit −₹0.0 Cr: core business −₹0.0 Cr, other income ₹0.0 Cr.

Core profit YoY: to loss

Cash & debt

FY25 cash from operations ₹0.3 Cr: 96% of FY25 net profit of ₹0.3 Cr.

Borrowings ₹0.4 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹2.9₹1.6 -42.3% below
Net profit₹0.2−₹0.0 -106.2% below

Parker Agrochem Exports Ltd

524628 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +327% above its own trend
  • Operating margin expanded 835 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +31.3%+52.5% 1.51.01.1
Operating profit +73.3%— 0.50.00.3
OPM % +835 bps+3242 bps 34.4%2.0%26.1%
Other income +0.0%+0.0% 0.00.00.0
Net profit +113.6%from loss 0.5-0.00.2
PAT margin % +1200 bps+3517 bps 31.1%-4.0%19.1%
EPS (₹) +113.0%from loss 0.98-0.080.46

Quality of profit

Core 98%Other income & one-offs 2%

Pre-tax profit ₹0.5 Cr: core business ₹0.5 Cr, other income ₹0.0 Cr.

Core profit YoY: +95.7% · reported profit +113.6%

Cash & debt

FY25 cash from operations ₹0.3 Cr.

Borrowings ₹1.1 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹2.3₹1.5 -34.3% below
Net profit₹0.1₹0.5 +327.3% above

Shukra Pharmaceuticals Ltd

524632 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit +423% above its own trend
  • Operating margin contracted 1884 bps YoY
  • All of pre-tax profit came from other income or one-off items
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +5.8%+9.1% 5.95.45.6
Operating profit to lossto loss -0.41.30.7
OPM % -1884 bps-3146 bps -7.0%24.5%11.9%
Other income +67.6%+54.1% 1.71.11.0
Net profit +340.7%+131.1% 2.41.00.5
PAT margin % +3076 bps+2137 bps 40.5%19.1%9.7%
EPS (₹) —+150.0% 0.050.020.01

No EPS growth against Sep 2024: ₹10 to ₹1 split in Mar 2025.

Quality of profit

Pre-tax profit ₹0.2 Cr: core business −₹1.5 Cr, other income ₹1.7 Cr.

Core profit YoY: loss widened · reported profit +340.7%

Cash & debt

FY25 cash from operations ₹8.0 Cr: 84% of FY25 net profit of ₹9.6 Cr.

Borrowings ₹4.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹4.9₹5.9 +18.8% above
Net profit₹0.5₹2.4 +422.7% above

Alufluoride Ltd

524634 · Q2 FY26 · Consolidated
M Cap
—
P/E
—
PEG
—
  • Profit +17% above its own trend
  • Operating margin expanded 556 bps YoY
  • Core business grew faster than reported profit (core profit +40%)
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +3.1%+25.3% 54.843.853.2
Operating profit +31.9%+94.3% 13.97.210.6
OPM % +556 bps+903 bps 25.4%16.4%19.9%
Other income -9.3%+14.7% 0.40.30.4
Net profit? +19.2%+155.8% 7.93.16.7
PAT margin % +196 bps+738 bps 14.5%7.1%12.5%
EPS (₹) +19.3%+156.1% 10.143.968.50

Quality of profit

Core 97%Other income & one-offs 3%

Pre-tax profit ₹11.3 Cr: core business ₹10.9 Cr, other income ₹0.4 Cr.

Core profit YoY: +40.5% · reported profit +19.2%

Cash & debt

FY25 cash from operations ₹12.0 Cr: 67% of FY25 net profit of ₹18.0 Cr.

Borrowings ₹30.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹65.3₹54.8 -16.1% below
Net profit₹6.8₹7.9 +16.9% above

Oxygenta Pharmaceutical Ltd

524636 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Operating margin contracted 1647 bps YoY
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +2.1%-5.5% 14.315.114.0
Operating profit loss widenedloss narrowed -4.6-6.8-2.2
OPM % -1647 bps+1318 bps -32.0%-45.1%-15.5%
Other income to lossto loss -0.10.20.8
Net profit loss widenedloss narrowed -4.9-6.1-2.9
PAT margin % -1413 bps+591 bps -34.5%-40.4%-20.3%
EPS (₹) loss widenedloss narrowed -1.33-1.65-0.80

Quality of profit

Pre-tax profit −₹6.4 Cr: core business −₹6.4 Cr, other income −₹0.1 Cr.

Core profit YoY: loss widened

Cash & debt

FY25 cash from operations ₹3.0 Cr.

Borrowings ₹62.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹28.0₹14.3 -49.0% below

Archit Organosys Ltd

524640 · Q2 FY26 · Standalone
M Cap
—
P/E
—
PEG
—
  • Profit -25% below its own trend
  • Operating margin contracted 143 bps YoY
  • 74% of pre-tax profit came from other income and one-off items
  • Profit grew faster than the core business (core profit -11%)
₹ CrYoYQoQ Sep 2025Jun 2025Sep 2024
Sales +11.2%-1.0% 32.933.229.5
Operating profit -5.3%-34.8% 2.74.12.9
OPM % -143 bps-425 bps 8.2%12.5%9.6%
Other income +131.7%+46.0% 1.51.00.6
Net profit +51.0%-24.5% 1.52.01.0
PAT margin % +123 bps-146 bps 4.7%6.1%3.5%
EPS (₹) +50.0%-24.2% 0.750.990.50

Quality of profit

Core 26%Other income & one-offs 74%

Pre-tax profit ₹2.0 Cr: core business ₹0.5 Cr, other income ₹1.5 Cr.

Core profit YoY: -10.5% · reported profit +51.0%

Cash & debt

FY25 cash from operations ₹19.0 Cr: 375% of FY25 net profit of ₹5.1 Cr.

Borrowings ₹28.0 Cr at Mar 2025.

Against its own trend ?

TrendActualGap
Sales₹34.7₹32.9 -5.3% below
Net profit₹2.0₹1.5 -24.5% below

How to read this page

The numbers. Each card is one company's Q2 FY26 results as filed with NSE or BSE, read from the filing within hours of its release, in ₹ crore. We show the consolidated statement, or the standalone one when the consolidated figures are a copy of it or have no year-ago quarter to compare with. YoY compares with the same quarter a year earlier and QoQ with the quarter before (the previous half-year for companies that report every six months). A swing between profit and loss is described in words: a percentage across it would mislead.

Net profit. On a consolidated statement, net profit is the profit of the whole group for the quarter, before minority interest. A company's own headline, and the AI read of its filing, often quote the profit attributable to its shareholders instead, which is lower when subsidiaries are partly owned: Larsen & Toubro's Q1 FY27 group profit was ₹4,988 Cr, of which ₹4,123 Cr belonged to its shareholders. EPS is worked out on that attributable profit, so EPS and net profit need not grow at the same rate. On a standalone statement the two are the same.

Margins. Operating margin (OPM) is operating profit, before depreciation, interest and other income, as a share of sales; PAT margin is net profit as a share of sales. Their changes are in basis points (100 bps = 1 percentage point).

Quality of profit. Core profit is operating profit minus interest and depreciation: what the business itself earned before tax. The rest of pre-tax profit is other income (interest on cash, dividends, gains on investments) and exceptional or one-off items. We flag a quarter when that share is 25% or more, and when reported profit grew much faster than core profit. For banks we compare pre-provision profit with net profit, since a fall in provisions can lift profit without the business growing.

Against its own trend. We do not have analyst consensus estimates, and we do not make them up. Instead each company is measured against the path it was on: the same quarter last year, grown at the median of its last four year-on-year growth rates (held between −50% and +100%; at least two growth rates needed). Sales 5% or more above that, or net profit 10% or more above, is "above trend"; as far below is "below trend". It answers "was this quarter better or worse than the company's own recent run?", which consensus does not.

Cash and debt. Profit is an accounting figure; cash is harder to dress up. For each company we show its operating cash flow for the last financial year as a share of that year's net profit (flagged under 50%, or when it is negative despite a profit), and its borrowings at the latest balance sheet against the one six months earlier (flagged at a 25% move). Balance sheets come with the September and March results, the year's cash-flow statement with the March results and the half-year's (April to September) with the September results.

Management guidance. When a company files the transcript of its earnings call, we read what its management said to expect: revenue or profit growth, margins, capex and the like, for this financial year or part of it. A figure is kept only when the sentence that states it is found in the transcript, and you can read it under "What management said". Growth and margins are then set beside the actual so far: the year-to-date quarters against the same quarters a year earlier (so the first half is measured against a full-year figure). Within 1 percentage point of the range for growth, or 0.5 for margins, is "on track"; above it "ahead", below it "behind". A new figure for the same period is marked raised or cut against the one before. This is what management said, not a forecast of ours.

Working capital. Inventory, trade receivables and trade payables from the same balance sheets, each also as days of sales (the amount against the twelve months' sales to that date, times 365). Receivables or inventory that grow 25 points or more faster than sales between two balance sheets (and by at least 20%) are flagged: money tied up in customers and stock is profit not yet in cash. These lines are read from filings since the September 2026 results, so comparisons with an earlier balance sheet start with the March 2027 results for most companies.

Price since results. The latest close against the last close before the filing (a filing after 3:30 pm counts from the next session). It is a fact about the market's reaction, not advice.

Market cap groups. Large cap is the 100 largest companies by market value and mid cap the next 150 (SEBI's ranking); below that, small cap is ₹5,000 Cr or more, micro cap ₹500 Cr or more, nano cap below.

⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI